RHOA and neoplasm: In our population, composed of 59 patients with nMTCL, the RhoA-mut/TET-2-mut association was demonstrated in 42.8% of cases with nMTCL-TFH-phenotype, also being associated with a high-tumor volume represented by bulky disease ≥ 7 cm and decreased overall response rates (ORR) to primary treatment based on anthracyclines (51).